Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis

Gouri M. Koduri, Chetan Mukhtyar

Research output: Contribution to journal › Editorial › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	559-560
Number of pages	2
Journal	Rheumatology
Volume	58
Issue number	4
DOIs	https://doi.org/10.1093/rheumatology/key097
Publication status	Published - 1 Apr 2019

Access to Document

@article{0b0b95446a974900b118e45a2c547fad,

title = "Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis",

author = "Koduri, {Gouri M.} and Chetan Mukhtyar",

year = "2019",

month = apr,

day = "1",

doi = "10.1093/rheumatology/key097",

language = "English",

volume = "58",

pages = "559--560",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis

AU - Koduri, Gouri M.

AU - Mukhtyar, Chetan

PY - 2019/4/1

Y1 - 2019/4/1

U2 - 10.1093/rheumatology/key097

DO - 10.1093/rheumatology/key097

M3 - Editorial

C2 - 29672739

SN - 1462-0324

VL - 58

SP - 559

EP - 560

JO - Rheumatology

JF - Rheumatology

IS - 4

ER -